---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-086140"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T08:19:38.149924+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical reports 2022 net loss of $23.0M; cash only $47K

## Summary
- Net loss $23.0M ($2.80/share) vs $4.6M ($0.63/share) in 2021; G&A expenses rose to $6.6M from $1.7M.
- Cash at Dec 31, 2022 was $47,000, down from $510,000; company raised $3.3M in March 2023 convertible debt.
- SCD device for adult AKI: NEUTRALIZE-AKI trial to enroll up to 200 patients; expects FDA PMA filing in Q3 2024.
- Pediatric AKI HDE application under FDA review; license/distribution agreement with Nuwellis for top 50 U.S. hospitals.
- R&D expenses flat at $2.8M; other expense surged to $11.4M from $0.2M, driven by $10.2M loss on forward option.

## SEC filing metadata
- accession: 0001193125-23-086140
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000119312523086140/0001193125-23-086140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000119312523086140/d492852d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-086140
- JSON: https://secwatch.observer/filing/0001193125-23-086140.json
- Plain text: https://secwatch.observer/filing/0001193125-23-086140.txt

## Key facts
- Earnings Releases
  SeaStar Medical Holding Corp reported the year ended December 31, 2022 results: net income $23.0 million, or $2.80 per share, EPS $2.80 per share.
  - Period: the year ended December 31, 2022
  - Net income: $23.0 million, or $2.80 per share
  - EPS: $2.80 per share
  - Result: reported results
  source text: SeaStar Medical Reports 2022 Financial Results and Provides a Business Update DENVER (March 30, 2023) – SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides a business update and reports financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831868/000119312523086140/0001193125-23-086140-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.